Water-Soluble Cannabinoid Achieves Higher Brain Levels and Reveals Potential for Sustained Active CBD Availability
Delivery of active compounds to the brain remains an important consideration in the development of brain-governed therapeutics, such as those targeting anxiety and other neurological challenges. Achieving meaningful exposure within brain tissue is a key objective when evaluating compounds intended to interact with neurological systems.
CBD82S™ and Brain Exposure
CBD is naturally lipophilic and water-insoluble, characteristics that can limit absorption, bioavailability, delivery, and overall pharmacokinetic performance.
Trait Biosciences’ proprietary technology converts conventional CBD into water-soluble cannabinoid forms, including CBD82S™. Trait CBDs are truly water-soluble cannabinoid ingredients innovated to improve absorption and bioavailability thereby enhanced efficacy while offering formulation and delivery flexibility without the need for added chemicals.
New preclinical findings from Trait Biosciences provide additional insight into the brain exposure of its proprietary water-soluble cannabinoid ingredient, CBD82S™, following topical administration. The findings show the presence of cannabinoid material within brain tissue, both as Trait material (CBD82S™) and as native CBD converted from CBD82S™. In addition to bioavailability and benefits of CBD being at the brain, the findings suggest potential sustained release of CBD from the CBD82S™ materials within brain tissue.
Potential for Sustained Active CBD Availability
The presence of CBD82S™ within brain tissue suggests that CBD82S™ may act as a reservoir of CBD within the brain, providing continued formation of CBD over time. This potential mechanism points to the opportunity of a sustained exposure of the brain to native CBD.
Understanding how cannabinoids reach and persist within brain tissue is an important area of research for advancing neurological challenges.
Trait Biosciences continues to advance its proprietary water-soluble cannabinoid technology platform and expands the reach of CBD benefits.
Being water-soluble, the Trait CBD offerings provide formulation and delivery flexibility across multiple potential routes of administration.
Looking Ahead
These findings expand the understanding of CBD82S™ and its potential behavior within brain tissue. Future research evaluating cannabinoid concentrations over time will help clarify the relationship between CBD82S™, native CBD formation, brain exposure, and duration of availability.
As cannabinoid research advances, improving absorption, bioavailability, and tissue exposure provide new opportunities for developing more predictable cannabinoid delivery strategies for pharmaceutical and other applications.
For additional information on the study, including study design, methodology, and detailed findings, please contact Trait Biosciences at info@traitbio.com.